About: Non-animal replacement methods for human vaccine potency testing: state of the science and future directions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Non-animal replacement methods for human vaccine potency testing: state of the science and future directions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Non-animal replacement methods for human vaccine potency testing: state of the science and future directions
Creator	Allen, David Arciniega, Juan Casey, Warren Descamps, Johan Finn, Theresa Horiuchi, Yoshinobu Isbrucker, Richard Lipscomb, Elizabeth Schmitt, Michael Sesardic, Dorothea Stickings, Paul Verthelyi, Daniela Johnson, Nelson Mcfarland, Richard
Source	Elsevier; Medline; PMC
abstract	Abstract NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods, and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. This report addresses methods and strategies identified by workshop participants for replacement of animals used for potency testing of human vaccines. Vaccines considered to have the highest priority for future efforts were (1) vaccines for which antigen quantification methods are already developed but not validated, (2) vaccines/components that require the largest number of animals, (3) vaccines that require an in vivo challenge test, and (4) vaccines with in vivo tests that are highly variable and cause a significant number of invalid tests. Vaccine potency tests identified as the highest priorities for replacement were those for diphtheria and tetanus, pertussis (whole cell and acellular), rabies, anthrax, polio vaccine (inactivated) and complex combination vaccines based on DT or DTwP/aP. Research into understanding the precise mechanism of protection afforded by vaccines and the identification of clinically relevant immunological markers are needed to facilitate the successful implementation of in vitro testing alternatives. This report also identifies several priority human vaccines and associated research objectives that are necessary to successfully implement in vitro vaccine potency testing alternatives.
has issue date	2011-12-31(xsd:dateTime)
bibo:doi	10.1016/j.provac.2011.10.002
bibo:pmid	32288913
has license	els-covid
sha1sum (hex)	fb9a554c308de802220fea4a907827a158580bbf
schema:url	https://doi.org/10.1016/j.provac.2011.10.002
resource representing a document's title	Non-animal replacement methods for human vaccine potency testing: state of the science and future directions
has PubMed Central identifier	PMC7129268
has PubMed identifier	32288913
schema:publication	Procedia in Vaccinology
resource representing a document's body	covid:fb9a554c308de802220fea4a907827a158580bbf#body_text
is schema:about of	named entity 'VACCINE POTENCY' named entity 'SAFETY' named entity 'PROGRAM' named entity 'cell' named entity 'alternatives' named entity 'based' named entity 'needed' named entity 'tests' named entity 'identified' named entity 'peer-review' named entity 'National Toxicology Program' named entity 'Safety' named entity 'WORKSHOP' named entity 'TESTS' named entity 'IMPLEMENTATION' named entity 'REDUCE' named entity 'SCIENCE' named entity 'CENTER' named entity 'SIGNIFICANT' named entity 'LARGEST' named entity 'RABIES' named entity 'QUANTIFICATION' named entity 'RELEVANT' named entity 'PRECISE' named entity 'IN VITRO' named entity 'ANIMALS' named entity 'VACCINE POTENCY' named entity 'IDENTIFIED' named entity 'VARIABLE' named entity 'REVIEW' named entity 'COMBINATION VACCINES' named entity 'TO IDENTIFY' named entity 'VETERINARY VACCINE' named entity 'UNDERSTANDING' named entity 'IDENTIFIED BY' named entity 'STATE' named entity 'STRATEGIES' named entity 'ANTHRAX' named entity 'NON-' named entity 'TESTING METHODS' named entity 'VACCINES' named entity 'TOXICOLOGY' named entity 'FUTURE' named entity 'ANIMAL' named entity 'METHODS' named entity '282' named entity 'CHALLENGE TEST' named entity 'METHODS' named entity 'TESTING' named entity 'TOXICOLOGICAL' named entity 'TO REDUCE' named entity 'PEER' named entity 'STATE' named entity 'NATIONAL' named entity 'REPLACEMENT' named entity 'RESPONSIBILITY' named entity 'ALTERNATIVE' named entity 'INTERNATIONAL' named entity 'DIRECTIONS' named entity 'TESTING' named entity 'TETANUS' named entity 'REPLACEMENT' named entity 'IMPROVED' named entity 'OBJECTIVES' named entity 'ANTIGEN' named entity 'PERTUSSIS' named entity 'HIGHLY' named entity 'ANIMAL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software